News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW. 

This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients? 

The top stories: 

 

 

Immunotherapy before surgery could better treat melanoma 


New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.
 

Read more… 

 

FDA clears first cancer gene therapy for trials  

 

The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial. 
 

Read more… 

 

Therapy could improve brain function in Alzheimer’s patients 

 

An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.
 

Read more… 

 

 

Sugar-targeting antibody could kill drug-resistant bacteria 

Researchers have designed antibodies that recognise the sugar found only on bacterial cells, which could underpin a new generation of immunotherapies for multidrug resistant hospital-acquired infections. 

 

Read more… 

 

 

UK government commits £1.5bn to life sciences 

 

Speaking at the BioIndustry Association (BIA)’s Gala Dinner, Liz Kendall, the Secretary of State for Science, Innovation and Technology, confirmed the funding for life sciences as part of the government’s pledge to scrap short-term funding cycles for key R&D institutions.
 

Read more…